Antibióticos (efectos secundarios de los)

2'-Fucosyllactose (2'-FL) is the most abundant human milk oligosaccharide (HMO) in breast milk and functions as a selective prebiotic for infant gut health. Clinical studies of 2'-FL-supplemented infant formula demonstrate it is safe, well-tolerated, and supports gut microbiota development by selectively stimulating bifidobacteria. Infants fed formula with 2'-FL showed improved gastrointestinal tolerance and immune benefits compared to unsupplemented controls.

Akkermansia muciniphila is a gut commensal that plays a key role in maintaining intestinal barrier integrity by metabolizing mucin and producing propionate and acetate. While most clinical research has focused on adults, emerging evidence suggests its abundance in early life correlates with healthy gut development and reduced risk of pediatric GI conditions including inflammatory bowel disease and obesity-related gut dysbiosis.

Multiple RCTs and a meta-analysis support B. clausii's benefit in children's gastrointestinal health, particularly for acute and persistent diarrhea. It has been shown to reduce duration of illness, stool frequency, and antibiotic-related GI side effects in pediatric populations. Spore-forming properties allow intact delivery to the intestine even in young children.

A randomized, double-blind, placebo-controlled multicenter study evaluated W. coagulans MTCC 5856 as adjunct therapy in children with acute diarrhea, finding good tolerability with no unexpected adverse events. The strain has GRAS status and pediatric safety data. IBS in children has also been studied with B. coagulans Unique IS-2.

Bifidobacterium species are the dominant beneficial bacteria in the infant gut and are well-documented in pediatric gastroenterology for improving digestive health. Over 100 clinical publications support their role in reducing diarrhea, improving gut microbiota balance, and supporting gut barrier function in infants and children. Multiple RCTs confirm efficacy in acute gastroenteritis and antibiotic-associated diarrhea.

Bifidobacterium adolescentis is a naturally occurring gut commensal that becomes increasingly relevant in the digestive microbiome of children as they transition to solid foods. It contributes to prebiotic fermentation and SCFA production. It is noted in the pediatric probiotic literature as part of the broader Bifidobacterium genus evidence base for gut health.

Bifidobacterium animalis, particularly the subspecies lactis (BB-12), is among the most-studied probiotic strains in pediatric populations. It has been evaluated in multiple RCTs for diarrhea, NEC, and antibiotic-associated GI symptoms in children and infants. Evidence from pediatric guidelines recognizes it as a relevant strain for infant digestive health.

Bifidobacterium bifidum is a key early-colonizing Bifidobacterium in the infant gut and has been used clinically to prevent diarrhea in hospitalized infants. A landmark 1994 Lancet RCT showed that feeding B. bifidum and Streptococcus thermophilus to hospitalized infants prevented diarrhea and rotavirus shedding. It is included in pediatric probiotic guidelines for select GI indications.

Bifidobacterium breve is a dominant Bifidobacterium species in breastfed infants and has been studied in RCTs for infantile colic, NEC prevention, and general gut microbiota modulation in early life. A 2021 RCT confirmed its efficacy for infantile colic treatment. It is among the strains recognized in pediatric GI guidelines.

Bifidobacterium infantis is the preeminent early-life gut colonizer in breastfed infants and is uniquely adapted to metabolize human milk oligosaccharides (HMOs). Clinical evidence supports its use in improving infant gut microbiota, reducing intestinal inflammation markers, and supporting gut barrier development. It is considered a foundational probiotic for infant digestive health.

Bifidobacterium lactis (B. animalis subsp. lactis) is one of the most widely studied probiotic strains in pediatric medicine, evaluated in clinical trials for diarrhea, NEC, H. pylori eradication-associated diarrhea, and gut tolerance in infants. It is a common addition to infant formulas and pediatric probiotic supplements with substantial safety data.

Bifidobacterium longum is a key species in the infant and child gut and has been studied for its role in reducing harmful gut bacteria, improving microbiota balance, and decreasing diarrhea frequency in children. Ingestion of B. longum-fortified yogurt has been shown to reduce Enterobacteriaceae and C. perfringens while increasing beneficial microflora in children.

Chamomile has a long traditional use in pediatric digestive complaints and specific clinical evidence for infantile colic. One RCT found that 57% of infants given chamomile-based tea had colic relief within a week versus 26% on placebo. Chamomile is also part of multi-herb preparations with confirmed efficacy for infant colic in clinical trials.

Bovine colostrum has evidence for supporting pediatric gut health, particularly for reducing infectious diarrhea in children. A PMC review documents that bovine colostrum shows promise for prevention and treatment of infectious diarrhea in infants and children, with several human studies showing positive effects against rotavirus and E. coli-induced diarrhea.

Fennel has both a long traditional history and clinical trial evidence specifically for infantile digestive conditions. A landmark RCT found fennel seed oil emulsion resolved colic symptoms in 65% of treated infants versus 24% on placebo. A systematic review meta-analysis confirms fennel-based preparations reduce crying duration in colicky infants by approximately 72 minutes/day.

Fructooligosaccharides (FOS) are well-established prebiotics widely added to infant formulas and pediatric nutritional products to support gut microbiota development. Clinical and in vitro studies in children confirm FOS increases beneficial gut bacteria (Bifidobacterium, Lactobacillus) and reduces harmful bacteria, supporting healthy digestive function. They are recognized by international bodies as safe and effective prebiotics in infant and child nutrition.

Galacto-oligosaccharides (GOS) are among the most evidence-supported prebiotics for infant and child gut health, widely used in infant formulas. Multiple clinical studies confirm GOS supplementation in infants sustains high levels of stool bifidobacteria, supports softer stools, and modulates gut microbiota favorably compared to unsupplemented formula. GOS are recommended in infant formula by international pediatric nutritional guidelines.

A randomized, double-blind, placebo-controlled trial in 52 pediatric patients (ages 4–17) demonstrated that alpha-galactosidase significantly reduced global distress (p=0.02), days with moderate-to-severe bloating (p=0.03), and the proportion of children experiencing flatulence (p=0.02). No adverse events were reported. Authors concluded the enzyme is a safe and effective treatment for gas-related symptoms in the pediatric population, though they noted that larger trials are needed.

A randomized, double-blind, placebo-controlled pilot study in children aged 8–18 with diarrhea-predominant IBS found that SBI at 10 g/day was safe and improved GI symptoms including stool number and abdominal pain. A pediatric case report also documented clinical and pathological remission of pediatric ulcerative colitis with SBI added to standard treatment.

Inulin is a well-characterized prebiotic fiber with clinical evidence for increasing beneficial gut bacteria in children. It selectively promotes Bifidobacterium growth, is commonly added to pediatric nutritional products, and supports healthy gut microbiota composition. Inulin is recognized as safe and effective for pediatric gut health by nutritional authorities.

Lactase is the enzyme that hydrolyzes lactose into glucose and galactose, addressing lactose intolerance—a common cause of digestive discomfort in children (gas, bloating, diarrhea). Lactase enzyme supplementation and lactase-fortified infant formulas are used clinically to manage lactose intolerance and reduce GI symptoms in affected children. Evidence supporting lactase use in pediatric lactose maldigestion is well-established.

The Lactobacillus genus (including multiple species) has extensive clinical evidence for improving digestive health in children, particularly for acute gastroenteritis, antibiotic-associated diarrhea, and infantile colic. Multiple RCTs and systematic reviews confirm that specific Lactobacillus strains (most notably L. rhamnosus GG and L. reuteri) are among the best-evidenced probiotics in pediatric GI medicine.

Lactobacillus acidophilus is a well-known probiotic strain studied for reducing gastrointestinal symptoms in children, including diarrhea duration and frequency during acute rotavirus gastroenteritis. It is among the probiotic strains evaluated in pediatric GI clinical trials and included in multi-strain pediatric probiotic products.

Lactobacillus casei has been evaluated in clinical trials for preventing and treating diarrhea in children attending day care centers. A landmark study found that supplementation with L. casei (strain DN-114 001) in milk ferment significantly reduced acute diarrhea in children in day care. It is among the probiotic strains recognized in pediatric GI literature.

L. paracasei strains have been tested in RCTs for children's gut health, including a synbiotic containing L. paracasei B21060 for acute diarrhea and L. paracasei N1115 for gut development in infants and toddlers. L. paracasei ST11 ameliorated non-rotavirus diarrhea in Bangladeshi children. Evidence is strain-specific and results vary across trials.

Lactobacillus reuteri DSM 17938 has strong clinical evidence specifically in pediatric populations for infantile colic (reducing crying time in breastfed infants), acute gastroenteritis (as adjunct to rehydration), and antibiotic-associated diarrhea prevention. Multiple RCTs and systematic reviews specifically in infants and children support its use.

Lactobacillus rhamnosus GG (LGG) is among the best-evidenced probiotic strains for children's digestive health globally. Multiple systematic reviews confirm its efficacy in treating acute gastroenteritis and preventing antibiotic-associated diarrhea in children. It is specifically recommended in multiple international pediatric GI guidelines.

Lactoferrin has been studied in children for prevention of neonatal sepsis, necrotizing enterocolitis, and infectious diarrhea with positive RCT results. A Cochrane review confirmed bovine lactoferrin reduces late-onset sepsis and necrotizing enterocolitis in preterm infants. A double-blind RCT also demonstrated reductions in diarrhea prevalence, duration, and severity in young children.

Enteric-coated peppermint oil has evidence of efficacy for functional abdominal pain and IBS in children. A double-blind RCT has shown PO to be effective in pediatric IBS and functional abdominal pain. International IBS guidelines acknowledge PO recommendations in pediatric contexts.

Peppermint oil has clinical evidence specifically in children for reducing functional abdominal pain (FAP) and IBS-related symptoms. A 2017 systematic review of 14 trials including 1,927 children found evidence for peppermint oil in decreasing duration, frequency, and severity of abdominal pain in pediatric functional GI disorders. Enteric-coated peppermint oil capsules are used in pediatric GI practice.

Psyllium has been studied in children for both IBS-related abdominal pain and functional constipation. A randomized, double-blind trial (Shulman et al., 2016; Clinical Gastroenterology and Hepatology; 85 children aged 7–18) found that psyllium reduced the mean number of IBS pain episodes roughly twice as much as placebo over 6 weeks. Systematic reviews have also documented psyllium's efficacy for improving stool frequency and consistency in pediatric functional constipation.

Saccharomyces boulardii is one of the two most recommended probiotic interventions in pediatric gastroenterology guidelines, alongside Lactobacillus rhamnosus GG. A 2022 systematic review and meta-analysis of 10 RCTs in 1,282 children under 5 confirmed it shortens diarrhea duration and reduces hospital stay in acute gastroenteritis. It is endorsed for pediatric use by multiple international guidelines.

Shen-chu (as Shenqu Xiaoshi Oral Liquid) has been evaluated in multiple RCTs for functional dyspepsia and functional constipation in children. A 2022 multicenter RCT (n=356 children, Rome IV criteria) demonstrated non-inferiority to domperidone syrup for pediatric functional dyspepsia. A 2026 systematic review and meta-analysis also found the formulation effective for pediatric functional constipation.

S. thermophilus-containing preparations have been studied in children for acute diarrhea, antibiotic-associated diarrhea, and IBS. A clinical study found S. thermophilus-based preparations reduced diarrhea symptoms by 50% vs. placebo in children. Fermented infant formulas with S. thermophilus showed favorable changes in stool patterns and diarrhea duration.

Sucrase (as sacrosidase) has robust clinical evidence specifically in pediatric populations with congenital sucrase-isomaltase deficiency (CSID). Randomized, double-blind trials in children aged 5 months to 11 years demonstrated that sacrosidase enzyme replacement resolves diarrhea and GI symptoms when a normal sucrose-containing diet is consumed. CSID typically manifests after weaning when sucrose-containing foods are introduced, making it primarily a childhood diagnosis.

Zinc is WHO-recommended for treating acute diarrhea in children under five as part of standard management alongside oral rehydration therapy. A 2024 systematic review and meta-analysis commissioned by WHO (38 RCTs) found zinc supplementation reduces diarrhea duration by approximately 13 hours and improves recovery rates in children with acute diarrhea. It is one of the most evidence-based micronutrients for children's digestive health.

Ajwain water is one of the most widely used traditional home remedies for infantile and childhood digestive complaints — including colic, gas, bloating, and stomach cramps — across South Asia. Traditional Ayurvedic texts specifically mention its use for children's digestive disorders. No pediatric clinical trials have been conducted.

Aloe vera gel has a long traditional history of use for soothing digestive complaints in children including constipation and gut irritation. Its mucilaginous polysaccharides (acemannan) coat the intestinal lining and have mild laxative effects. Traditional use in children for digestive complaints is documented across multiple cultures, though large pediatric-specific clinical trials are limited.

Bacopa (Bacopa monnieri) is used in Ayurvedic medicine as a digestive tonic, with traditional applications including support for digestive health and gut motility in children, alongside its well-known use as a cognitive herb. Traditional Ayurvedic texts reference Bacopa for GI complaints including constipation and dyspepsia.

Caraway has traditional use as a colic remedy and carminative in infants and children across European and Ayurvedic traditions. The EMA HMPC and Health Canada (NHPID) reference traditional use in children for digestive symptoms. Caraway oil is noted as usable topically as an anti-colic and carminative agent in infants.

Ginger has been used for thousands of years in Ayurvedic, Traditional Chinese, and folk medicine systems to soothe childhood digestive complaints including nausea, vomiting, and stomachache. Its bioactive gingerols and shogaols stimulate digestive enzyme secretion, accelerate gastric emptying, and exert antispasmodic effects. While most clinical trial evidence is in adults, traditional pediatric use is cross-culturally widespread.

Slippery elm bark has a long history of use in North American traditional and herbal medicine as a demulcent remedy for children's digestive complaints including diarrhea, gut irritation, and inflammatory bowel conditions. Its mucilaginous inner bark coats and soothes the GI tract. Traditional use is well-documented, though large pediatric-specific RCTs are absent.